Modern Systemic Therapy for Metastatic Renal Cell Carcinoma of the Clear Cell Type

被引：8
|
作者：
Parikh, Mamta [1 ]
Lara, Primo N., Jr. [1 ]
机构：
[1] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95819 USA
来源：
ANNUAL REVIEW OF MEDICINE, VOL 69 | 2018年 / 69卷
关键词：
checkpoint inhibitor; immunotherapy; mTOR; angiogenesis; LONG-TERM SAFETY; OPEN-LABEL; PHASE-II; INTERFERON ALPHA-2A; CLINICAL ACTIVITY; DOUBLE-BLIND; SUNITINIB; EVEROLIMUS; CANCER; SORAFENIB;
D O I：
10.1146/annurev-med-041916-124132
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
In the last 30 years, there have been many advances in the treatment of metastatic renal cell carcinoma of the clear cell type. Renal cell carcinoma has long been understood to have a component of immune mediation and has been responsive to immune-based therapies; in addition to early cytokine therapy, newer checkpoint inhibition therapies have also demonstrated activity. Molecular characterization of the genome of clear cell renal cell carcinoma enabled identification of the roles of angiogenesis and hypoxic stress. This led to development of small-molecule tyrosine kinase inhibitors and inhibitors of mammalian target of rapamycin that have provided additional benefit to patients. Ongoing strategies of combinations of immune and antiangiogenic therapies may lead to further advancements.
引用
收藏
页码：209 / 221
页数：13
相关论文
共 50 条
  • [1] Efficacy of systemic therapy for metastatic non clear renal cell carcinoma
    Mizuno, R.
    Takamatsu, K.
    Hayakawa, N.
    Tanaka, N.
    Kosaka, T.
    Oya, M.
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 : 192 - 192
  • [2] The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy
    van der Mijn, Johannes C.
    Eng, Kenneth W.
    Chandra, Pooja
    Fernandez, Evan
    Ramazanoglu, Sinan
    Sigaras, Alexandros
    Oromendia, Clara
    Gudas, Lorraine J.
    Tagawa, Scott T.
    Nanus, David M.
    Faltas, Bishoy F.
    Beltran, Himisha
    Sternberg, Cora N.
    Elemento, Olivier
    Sboner, Andrea
    Mosquera, Juan Miguel
    Molina, Ana M.
    [J]. MOLECULAR ONCOLOGY, 2022, 16 (12) : 2384 - 2395
  • [3] Trends in Initial Systemic Therapy for Elderly Patients with Metastatic Clear Cell Renal Cell Carcinoma
    Osterman, Chelsea K.
    Deal, Allison M.
    Milowsky, Matthew, I
    Bjurlin, Marc A.
    Rose, Tracy L.
    [J]. KIDNEY CANCER, 2020, 4 (03) : 131 - 137
  • [4] Update on systemic therapy for clear cell renal cell carcinoma
    Josef Mühlmann
    [J]. memo - Magazine of European Medical Oncology, 2023, 16 : 38 - 41
  • [5] Update on systemic therapy for clear cell renal cell carcinoma
    Muehlmann, Josef
    [J]. MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2023, 16 (01) : 38 - 41
  • [6] Systemic Therapy for Metastatic Renal Cell Carcinoma
    Kramer, M. W.
    Steffens, S.
    von Klot, C.
    Merseburger, A. S.
    Kuczyk, M. A.
    [J]. AKTUELLE UROLOGIE, 2012, 43 (04) : 265 - 268
  • [7] Systemic therapy of metastatic renal cell carcinoma
    Maute, Luise
    Bergmann, Lothar
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2016, 141 (07) : 466 - 469
  • [8] Systemic therapy of metastatic renal cell carcinoma
    Autenrieth, M.
    Heidenreich, A.
    Gschwend, J. E.
    [J]. UROLOGE, 2006, 45 (05): : 594 - 599
  • [9] Systemic Therapy for Metastatic Renal Cell Carcinoma
    Kroog, Glenn S.
    Motzer, Robert J.
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2008, 35 (04) : 687 - 701
  • [10] Systemic therapy of metastatic renal cell carcinoma
    Maute, L.
    Bergmann, L.
    [J]. ONKOLOGE, 2015, 21 (01): : 35 - +
12345